Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-alpha and -beta (IFN-alpha/beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-alpha/beta, accompanied by an increase in p53 protein level. IFN-alpha/beta signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-alpha/beta contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In response to senesce-inducing stimuli, senescent cells produce, in a cGAS-dependent manner, type I interferons that have pro-senescence and anti-proliferative activities.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
In the citing paper
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“2a ); ISRE is activated by the IFN-activated transcription factor ISGF3, a heterotrimeric complex consisting of a signal transducer and activator of transcription factor 1 (Stat1), Stat2 and interferon regulatory factor 9 (IRF-9”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Previous studies have shown that p53 -deficient mice show no sign of abnormality in T and B cells, and that they can mount adaptive immune responses normall”
ResultMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024 · cited 1×
“Persistent infection with oncogenic HPV types represents a major risk factor for the development of cervical cancer, in which E6 is known to have a critical role (together with another oncoprotein, E7 (ref”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“We infer that, similar to DNA damage, ATM activation is caused by changes in the chromatin structure in virus-infected cell”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“We also examined the effect of IFN-β on the DNA damage-induced apoptotic response of MEFs expressing the adenovirus E1A oncoprotein, as it is well known that this response is p53-dependent and critical for tumour suppressio”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Self-citation
Research works printed but not linked: 1
- Vilcek, J. & Sen, G. S. in Fields Virology 3rd edn (eds Fields, D. M., Knipe, P. M. & Howley, P. M.) 375–399 (Lippincott-Raven, Philadelphia, 1996)
Cited by
Items 501–600 of 867
Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117358 · Cited by 21
SUMO and Cytoplasmic RNA Viruses: From Enemies to Best Friends
Motiam, A. E., Vidal, S., Seoane, R., Bouzaher, Y. H., González, J., & Rivas, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38266-7_11 · Cited by 21
Kanda, T., Yokosuka, O., Imazeki, F., Arai, M., & Saisho, H. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.805 · Cited by 19
Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma?
Masuda, A., Kamai, T., Abe, H., Arai, K., & Yoshida, K. (2009) · Biomedical Research · doi:10.2220/biomedres.30.171 · Cited by 19
Pestka, S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00193-4 · Cited by 19
Chattopadhyay, S., Hazra, R., Mallick, A., Gayen, S., & Roy, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189110 · Cited by 21
Zhang, Y., Hao, J., Zeng, J., Li, Q., Rao, E., Sun, Y., Liu, L., Mandal, A., Landers, V. D., Morris, R. J., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.02.041 · Cited by 20
“Given the observations that IFN-b induces p53 gene transcription and protein production for anti-tumor and anti-viral defense (Takaoka et al., 2003), we speculated that IFN-l might exert similar functions in inducing the p53 response.”
BackgroundHuang, T., Jiang, C., Yang, M., Xiao, H., Huang, X., Wu, L., & Yao, M. (2020) · Veterinary Research · doi:10.1186/s13567-020-00828-3 · Cited by 20
Inhibition of Pim1 kinase reduces viral replication in primary bronchial epithelial cells
de Vries, M., Smithers, N. P., Howarth, P. H., Nawijn, M. C., & Davies, D. E. (2015) · European Respiratory Journal · doi:10.1183/09031936.00206514 · Cited by 19
Watanabe, S., & Inoue, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068671 · Cited by 18
Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge
Sun, J., Ennis, J., Turner, J. D., & Chu, J. J. H. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.09.003 · Cited by 18
Sakisaka, M., Haruta, M., Komohara, Y., Umemoto, S., Matsumura, K., Ikeda, T., Takeya, M., Inomata, Y., Nishimura, Y., & Senju, S. (2016) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.422 · Cited by 21
Huang, T., Huang, X., Shi, B., Wang, F., Feng, W., & Yao, M. (2018) · Veterinary Research · doi:10.1186/s13567-018-0616-9 · Cited by 21
Franco, A. (2005) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2005.01596.x · Cited by 20
Matsumoto, K., Okano, J., & Murawaki, Y. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1616-x · Cited by 19
Suresh, V., Dash, P., Suklabaidya, S., Murmu, K. C., Sasmal, P. K., Jogdand, G. M., Parida, D., Sethi, M., Das, B., Mohapatra, D., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202101953r · Cited by 17
Potential cGAS-STING pathway functions in DNA damage responses, DNA replication and DNA repair
Zierhut, C. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103608 · Cited by 20
Regulation of cellular senescence by innate immunity
Hou, J., Zheng, Y., & Gao, C. (2023) · Biophysics Reports · doi:10.52601/bpr.2023.230032 · Cited by 18
“In the same year, Tadatsugu Taniguchi's laboratory found that in response to DNA damage, IFN-I increased the expression of p53 and cooperated with stressful events to activate p53 (Takaoka et al. 2003).”
BackgroundNiu, R., Zheng, Q., Zhang, J., & Zhang, H. (2013) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2013.10.005 · Cited by 17
Guo, H., Fu, X., Lin, Q., Liu, L., Liang, H., Huang, Z., Li, N., & Su, J. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.09.039 · Cited by 18
E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers
Bandilovska, I., Keam, S. P., Gamell, C., Machicado, C., Haupt, S., & Haupt, Y. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz072 · Cited by 17
Novel modulators of p53-signaling encoded by unknown genes of emerging viruses
Alzhanova, D. V., Corcoran, K., Bailey, A., Long, K. M., Taft-Benz, S., Graham, R. L., Broussard, G. S., Heise, M. T., Neumann, G., Halfmann, P., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009033 · Cited by 17
Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Caraglia, M., Dicitore, A., Marra, M., Castiglioni, S., Persani, L., Sperlongano, P., Tagliaferri, P., Abbruzzese, A., & Vitale, G. (2013) · Protein and Peptide Letters · doi:10.2174/0929866511320040005 · Cited by 19
Sugihara, T., Murano, H., Nakamura, M. M., Ichinohe, K., & Tanaka, K. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0358 · Cited by 17
IRF9 promotes apoptosis and innate immunity by inhibiting SIRT1-p53 axis in fish
Jiang, Z., Weng, P., Xu, X., Li, M., Li, Y., Lv, Y., Chang, K., Wang, S., Lin, G., & Hu, C. (2020) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2020.05.038 · Cited by 17
Wittnebel, S., Jalil, A., Thiery, J., DaRocha, S., Viey, E., Escudier, B. J., Chouaı̈b, S., & Caignard, A. (2005) · PubMed · Cited by 17
Combination Therapy with S-1 and Pegylated Interferon Alpha for Advanced Hepatocellular Carcinoma
Ueshima, K., Kudo, M., Nagai, T., Tatsumi, C., 上田, 泰., Takahashi, S., Hatanaka, K., Kitai, S., Ishikawa, E., Inoue, T., et al. (2008) · Oncology · doi:10.1159/000173431 · Cited by 17
The innate antiviral response upregulates IL-13 receptor α2 in bronchial fibroblasts
Campbell-Harding, G., Sawkins, H., Bedke, N., Holgate, S. T., Davies, D. E., & Andrews, A.-L. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.08.030 · Cited by 16
Zhang, X., Liu, D., Zhang, S., Wei, X., Song, J., Zhang, Y., Jin, M., Shen, Z., Wang, X., Feng, Z., et al. (2015) · Scientific Reports · doi:10.1038/srep09722 · Cited by 23
Targeting calpains: A novel immunomodulatory approach for microbial infections
Kumar, V., & Ahmad, A. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.002 · Cited by 19
Association of HCV mutated proteins and host SNPs in the development of hepatocellular carcinoma
Suhail, M., Sohrab, S. S., Qureshi, A., Tarique, M., Abdel-Hafiz, H. A., Alghamdi, K., & Qadri, I. (2018) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2018.02.034 · Cited by 17
Li, J., Mao, L., Li, W., Hao, F., Zhong, C., Zhu, X., Ji, X., Yang, L., Zhang, W., Liu, M., et al. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00093 · Cited by 16
Natural Products Mediated Targeting of Virally Infected Cancer
Fatima, I., Kanwal, S., & Mahmood, T. (2019) · Dose-Response · doi:10.1177/1559325818813227 · Cited by 16
“Inborn immune surveillance signaling along with cancer suppressor signaling processes initiates apoptotic pathways.(31) Hence, targeting of tumor suppressor pathways by viruses depicts an immune evasion response that impairs antiviral pathways but keeps the affected cell at danger for cancerous growth (known as anti-a…”
BackgroundAmeh-Mensah, C., Duduyemi, B. M., Bedu-Addo, K., Manu, E. A., Opoku, F., & Titiloye, N. A. (2021) · Journal of Oncology · doi:10.1155/2021/7054134 · Cited by 20
“7% recorded in this study) has a potential to alter the apoptotic pathway and result in tumorigenesis [11].”
BackgroundEBV: Immunobiology and host response
Moss, D. J., Burrows, S. R., & Khanna, R. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545313.052 · Cited by 16
NF‐κB p50 and p65 subunits control intestinal homeostasis
Gadjeva, M. G., Wang, Y., & Horwitz, B. H. (2007) · European Journal of Immunology · doi:10.1002/eji.200737186 · Cited by 17
Tu, H., Chen, Y., Chiu, H. ‐., Chin, Y., Huang, S., Cheng, L. ‐., Fu, E., & Chiang, C. (2009) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2008.01189.x · Cited by 16
Restriction of human herpesvirus 6B replication by p53
Øster, B., Kofod‐Olsen, E., Bundgaard, B. B., & Höllsberg, P. (2008) · Journal of General Virology · doi:10.1099/vir.0.83262-0 · Cited by 16
“Virus infection is one of the cellular stress factors that can potentially activate p53 (Takaoka et al., 2003).”
BackgroundKSHV manipulation of the cell cycle and apoptosis
Moore, P. S. (2007) · Europe PMC (PubMed Central) · Cited by 17
Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers
Odnokoz, O., Yu, P., Peck, A. R., Sun, Y., Kovatich, A. J., Hooke, J. A., Hu, H., Mitchell, E. P., Rui, H., & Fuchs, S. Y. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1750297 · Cited by 20
Interferon-3/Limitin: Novel Type I Interferon That Displays a Narrow Range of Biological Activity
Oritani, K., & Tomiyama, Y. (2004) · International Journal of Hematology · doi:10.1532/ijh97.04087 · Cited by 16
Hagiwara, S., Kudo, M., Ueshima, K., Chung, H., Yamaguchi, M., Takita, M., Haji, S., Kimura, M., Arao, T., Nishio, K., et al. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0294-5 · Cited by 15
Zimran, E., Zingariello, M., Bochicchio, M. T., Bardelli, C., & Migliaccio, A. R. (2019) · F1000Research · doi:10.12688/f1000research.18581.1 · Cited by 15
Fahl, S. P., Sertori, R., Zhang, Y., Contreras, A. V., Harris, B. D., Wang, M., Perrigoue, J., Balachandran, S., Kennedy, B. K., & Wiest, D. L. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100668 · Cited by 15
FOXL2 and FOXA1 cooperatively assemble on the TP53 promoter in alternative dimer configurations
Choi, Y., Luo, Y., Lee, S., Jin, H., Yoon, H., Hahn, Y., Bae, J., & Lee, H. H. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac673 · Cited by 17
Yao, P., Xiao, P., Huang, Z., Tang, M., Tang, X., Yang, G., Zhang, Q., Li, X., Yang, Z., Xie, C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00608-w · Cited by 19
Yi, J., Lin, P., Li, Q., Zhang, A., & Kong, X. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.08.010 · Cited by 17
Khan, R. T., Sancho‐Shimizu, V., Prendergast, C., Roy, M.-F., Loredo‐Osti, J. C., & Malo, D. (2011) · Genes and Immunity · doi:10.1038/gene.2011.69 · Cited by 17
Abramowski, P., Otto, B., & Martinꝉ, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091970 · Cited by 15
Immunotherapy for advanced or relapsed cervical cancer
Lin, C., Wang, C., & Lai, C. (2013) · Gynecology and Minimally Invasive Therapy · doi:10.1016/j.gmit.2012.12.001 · Cited by 15
Coffea arabica Bean Extracts and Vitamin C: A Novel Combination Unleashes MCF-7 Cell Death
El‐Garawani, I. M., El‐Nabi, S. H., El-Shafey, S., Elfiky, M. M., & Nafie, E. H. O. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666190822161337 · Cited by 18
Li, Y., Jiang, N., Fan, Y., Zhou, Y. K., Liu, W., Xue, M., Meng, Y., & Zeng, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246149 · Cited by 15
The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver
Leu, J. I.-J., Murphy, M. E., & George, D. L. (2013) · Journal of Liver · doi:10.4172/2167-0889.1000117 · Cited by 15
Sakthivel, D., Vignesh, A. R., Raj, G. D., Reddy, Y. K., Raja, A., & Tirumurugaan, K. G. (2013) · Veterinary Research Communications · doi:10.1007/s11259-013-9579-5 · Cited by 15
“IFN-α is well known to clear the virally infected cells through apoptosis, triggering potent pro-inflammatory cytokines and nitric oxide production to prevent the spread of virus (Takaoka et al. 2003; Mattner et al. 2000).”
BackgroundPang, R., Tao, J., Zhang, S., Chen, K., Zhao, L., Yue, X., Wang, Y., Ye, P., Zhu, Y., & Wu, J. (2010) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/neq011 · Cited by 15
“p53 is also essential for a host’s antiviral innate immune responses [28].”
Gastrointestinal organoids in the study of viral infections
Gebert, J. T., Scribano, F. J., Engevik, K. A., Perry, J. L., & Hyser, J. M. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00152.2022 · Cited by 17
Lim, H.-Y., Han, J., Yoon, H., & Jang, K. L. (2022) · Viruses · doi:10.3390/v14102313 · Cited by 15
Liu, W., Yang, H., Su, W.-C., Wang, C.-C., Chen, H., Wang, H., Huang, W., Chen, D., & Lai, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043824 · Cited by 16
Lee, J.-H., Adler, F. R., & Kim, P. (2017) · Bulletin of Mathematical Biology · doi:10.1007/s11538-017-0315-0 · Cited by 16
Chromosomal instability upregulates interferon in acute myeloid leukemia
Jin, N. Y., Lera, R. F., Yan, R. E., Guo, F., Oxendine, K., Horner, V. L., Hu, Y., Wan, J., Mattison, R. J., Weaver, B. A. A., et al. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22880 · Cited by 17
Fang, S., Zhang, K., Wang, T., Wang, X., Lü, X., Peng, B., Wu, W., Zhang, R., Chen, S., Zhang, R., et al. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5852-y · Cited by 14
Chaturvedi, V., Bodner, B. K., Qin, J., & Nickoloff, B. J. (2005) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2005.10.003 · Cited by 14
“Given the increasing interest in defining the cross-talk between interferon signaling and p53 [22—24], further studies are indicated to determine the range of cell types in which IFN-a plus IFN-g trigger both p53 dependent as well as p53-independent apoptosis [53].”
BackgroundOie, S., Ono, M., Fukushima, H. S., Hosoi, F., Yano, H., Maruyama, Y., Kojiro, M., Terada, T., Hirano, K., Kuwano, M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0281 · Cited by 14
“(24) showed that transcription of the p53 gene is induced by IFN-a/IFN-h, accompanied by an increase in p53 protein level, and that the apoptotic response by IFN-h combined with 5-FU was enhanced.”
BackgroundEvaluation of Innate Immune Signaling Pathways in Transformed Cells
Heiber, J. F., & Barber, G. N. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-340-0_15 · Cited by 14
HIV infection reprogrammes CD4+ T cells for quiescence and entry into proviral latency
Plasek, L., Gunawardane, L. S., Niazi, F., Mbonye, U. R., Leskov, K., Perez, G., Dobrowolski, C. N., Shukla, M., Nutt, W. S., Karn, J., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02128-y · Cited by 21
Genetic Markers of Recurrence in Colorectal Cancer
Smolle, M. A., Pichler, M., Haybaeck, J., & Gerger, A. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.83 · Cited by 14
Botting, C., Lu, X., & Triezenberg, S. J. (2016) · Virology Journal · doi:10.1186/s12985-016-0470-1 · Cited by 13
Systemic virotherapy for multiple myeloma
Oliva, S., Gambella, M., Boccadoro, M., & Bringhen, S. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1364359 · Cited by 14
Mathematical model of STAT signalling pathways in cancer development and optimal control approaches
Lee, J., Lee, D., & Kim, Y. (2021) · Royal Society Open Science · doi:10.1098/rsos.210594 · Cited by 13
Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis
Tong, R., Feng, L., Zhang, L., Zhang, J., Mao, Y., Zhang, K., Gao, Y., Wang, G., & Cheng, S. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0061 · Cited by 16
Kawamoto, S.-I., Oritani, K., Asakura, E., Ishikawa, J., Koyama, M., Miyano, K., Iwamoto, M., Yasuda, S.-I., Nakakubo, H., Hirayama, F., et al. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.06.008 · Cited by 13
Role of p53 family in birth defects: Lessons from zebrafish
Danilova, N., Sakamoto, K. M., & Lin, S. (2008) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20129 · Cited by 14
p53 mediated IFN-β signaling to affect viral replication upon TGEV infection
Ding, L., Li, J., Li, W., Fang, Z., Li, N., Guo, Q., Qu, H., Feng, D. Q., Li, J., & Hong, M. (2018) · Veterinary Microbiology · doi:10.1016/j.vetmic.2018.10.025 · Cited by 13
Kohli, V., Singhal, A., Elliott, L., & Jalil, S. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01396.x · Cited by 14
Control of virus infection by tumour suppressors
Muñoz‐Fontela, C., García, M. Á., Collado, M., Marcos-Villar, L., Gallego, P. P. F., Estéban, M., & Rivas, C. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm048 · Cited by 14
“[42].”
BackgroundImpact of lymphocyte apoptosis on the innate immune stages of infection
Carrero, J. A., & Unanue, E. R. (2007) · Immunologic Research · doi:10.1007/s12026-007-0017-z · Cited by 13
Hunger, A., Medrano, R. F. V., & Strauss, B. E. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.201 · Cited by 13
The immunomodulatory effects of cannabidiol on Hsp70-activated NK cells and tumor target cells
Wang, F., Dezfouli, A. B., & Multhoff, G. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.07.008 · Cited by 14
Tumor suppressor p53 protects mice against Listeria monocytogenes infection
Wang, S., Liu, P., Wei, J., Zhu, Z., Shi, Z., Shao, D., & Ma, Z. (2016) · Scientific Reports · doi:10.1038/srep33815 · Cited by 12
Li, W., Deng, P., Wang, J., Li, Z., & Zhang, H. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa087 · Cited by 12
Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia
Forthun, R. B., Hellesøy, M., Sulen, A., Kopperud, R. K., Sjøholt, G., Bruserud, Ø., McCormack, E., & Gjertsen, B. T. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02931-1 · Cited by 12
Cloning of IP15, a pancreatitis-induced gene whose expression inhibits cell growth
Ropolo, A., Tomasini, R., Grasso, D., Dusetti, N., Cerquetti, M. C., Iovanna, J., & Vaccaro, M. I. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.085 · Cited by 12
Yuan, X.-W., Zhu, X., Liang, S.-G., Fan, Q., Chen, Z.-X., Huang, X.-F., Sheng, P.-Y., He, A.-S., Yang, Z.-B., Deng, R., et al. (2008) · Life Sciences · doi:10.1016/j.lfs.2007.11.025 · Cited by 12
Patel, B., Zhou, Y., Babcock, R. L., Ma, F., Zal, M. A., Kumar, D., Medik, Y. B., Kahn, L. M., Pineda, J. E., Park, E. M., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02218-6 · Cited by 15
“…IFN-II, provided exogenously or elicited with infection, have direct and indirect effects on hematopoiesis [12, 13], including promotion of biased differentiation towards myeloid and megakaryocyte lineages [14, 55, 56], enhanced HSC proliferation, and activation of p53-mediated apoptosis [12, 15].”
Striking the right balance with type I interferon signalling in cancer
Chadwick, T. B., So, J., Hertzog, P. J., Haynes, N. M., & Parker, B. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00915-1 · Cited by 16
“In epithelial and tumour cells, type I IFN signalling integrates with p53-regulated, NF-κB-regulated and MAPK-regulated pathways to enforce cytostatic, apoptotic or senescence responses that limit proliferation and enhance immune recognition 53 .”
Srivastava, P., Chaudhary, S., Malhotra, S., Varma, B., & Sunil, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17158 · Cited by 11
Hiebinger, F., Kudulyte, A., Chi, H., de Lara, S. B., Ilic, D., Helm, B., Welsch, H., Thi, V. L. D., Klingmüller, U., & Binder, M. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03150-y · Cited by 13
Zhu, Z., Wei, J., Shi, Z., Yang, Y., Shao, D., Li, B., Wang, X., & Ma, Z. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.074 · Cited by 15
Hamdi, N., Elakel, W., El‐Serafy, M., Esmat, G., Sarrazin, C., & Abdelaziz, A. I. (2011) · Intervirology · doi:10.1159/000327783 · Cited by 11
Li, Q., Kawamura, K., Yang, S., Okamoto, S., Kobayashi, H., Tada, Y., Sekine, I., Takiguchi, Y., Shingyouji, M., Tatsumi, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072709 · Cited by 11
“demonstrated that type I IFNs upregulated expression of the p53 gene, suggesting a possible role of p53 in the type I IFN-mediated anti-tumor effects [14].”
BackgroundUchino, K., Obi, S., Tateishi, R., Sato, S., Kanda, M., Sato, T., Arano, T., Enooku, K., Goto, E., Masuzaki, R., et al. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0574-3 · Cited by 11
“Furthermore, other studies have revealed the mechanism underlying the antitumor effects of this combination therapy [24–31].”
ResultPark, M. S., Kim, B.-R., Kang, S., Kim, D.-Y., & Rho, S. B. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.37 · Cited by 11
Janeth Fernández, P., Méndez‐Sánchez, S. C., González-Correa, C.-A., & Miranda, D. A. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.10.026 · Cited by 15
Xue, B.-H., Liu, Y., Hu, C., Sun, Y. T., & Yu, W. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03791-x · Cited by 11
Cerqueira, O. L. D., Clavijo-Salomon, M. A., Cardoso, E. C., Tortelli, T. C., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576658 · Cited by 14
“In addition to its role in immune activation, the IFNb pathway is also known to promote cell death via the p53/p14ARF axis (28, 29).”
BackgroundAntiviral Activity of Oridonin Against Herpes Simplex Virus Type 1
Jiang, K., Feng, J., Qi, X., Ran, L., & Xie, L. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s387885 · Cited by 11
Mauro, F. R., Giannarelli, D., Galluzzo, C. M., Visentin, A., Frustaci, A. M., Sportoletti, P., Vitale, C., Reda, G., Gentile, M., Levato, L., et al. (2023) · Cancers · doi:10.3390/cancers15112993 · Cited by 11
Damdinsuren, B., Nagano, H., & Monden, M. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00191.x · Cited by 11
Hu, Y., Li, X. A., Xiong, S., Ma, Q., Liu, D., Shi, Z.-Q., Tang, J., Rao, X., Hu, F., & Li, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15352 · Cited by 11
Shi, X., Jia, Y., Xie, X., & Li, S. (2017) · Genes & Genetic Systems · doi:10.1266/ggs.16-00024 · Cited by 11
Metadata
- Authors
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., & Taniguchi, T.
- Affiliations
- The University of Tokyo (JP)
- University of Vienna (AT)
- Sapporo Medical University (JP)
- Corresponding author
- Taniguchi, Tadatsugu
- ORCID
- Venue
- Nature
- Published
- 2003-07
- Volume
- 424
- Issue
- 6948
- Pages
- 516-523
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2119885778
- Cited by
- 847
- References
- 51
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 32 · 2020: 41 · 2019: 40 · 2018: 21 · 2017: 38 · 2016: 50 · 2015: 44 · 2014: 40 · 2013: 46 · 2012: 38
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Boehringer Ingelheim Japan
- Senri Life Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, type I interferon, interferon signaling, tumor suppression, antiviral defense, apoptosis, viral infection, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Humans, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Vesicular stomatitis Indiana virus, Signal Transduction, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Interferon-alpha, Interferon-beta, Apoptosis, Response Elements, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.